This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The pharmaceutical industry has undergone significant changes over the past decade, with a growing trend towards outsourcing key aspects of research, development, and manufacturing to third-party vendors. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48
It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drugdevelopment. It demands a comprehensive, collaborative approach that reduces complexity and allows for just-in-time decision-making throughout the drugdevelopment journey. billion in 2023 to 1.2
It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. Long-term sustainability may benefit from identifying priority indications, exploring emerging mechanisms of action and refining development priorities.
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceuticaldrugdevelopment has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drugdevelopment.
Accelerating Generic DrugDevelopment: Strategies for Success As a pharmaceutical professional, you know how crucial it is to navigate the complex landscape of generic drugdevelopment. The generic drugdevelopment process involves several stages, from patent research to regulatory approvals.
The Unsung Heroes of Generic DrugDevelopment: The Power of Partnerships As we navigate the complex landscape of pharmaceuticals, it's easy to overlook the crucial role that partnerships play in bringing affordable, life-saving medications to market. When it comes to developing generic drugs, partnerships can take many forms.
The pharmaceutical industry is undergoing significant transformations, particularly in the realm of generic drugdevelopment. Recent trends and advancements in technology, research, and collaboration are reshaping the landscape of generic drugdevelopment, leading to new opportunities and challenges for pharmaceutical companies.
As the pharmaceutical industry continues to evolve, drugdevelopers encounter new challenges and opportunities in their pursuit of innovation. These annual results provide valuable insights into the state of drugdevelopment, highlighting shifts in industry practices and illuminating emergent areas of focus.
This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects. Your DrugsDevelopment Stage The stage of your drugdevelopment is a critical factor in selecting a CDMO.
Drug patent prosecution is a complex and critical process that can make or break the success of a new medication. As a business professional in the pharmaceutical industry, understanding and implementing effective strategies for drug patent prosecution can be the difference between market domination and missed opportunities.
By: Juliane Mills, Senior Director, Therapeutic Strategy Lead, Rare Disease The rise of patient-led clinical research, particularly in rare disease, represents a significant shift in the clinical trial landscape. Why Is There an Increase in Patient-Led Rare Disease Research?
In the vast realm of pharmaceuticalresearch and development, there’s a fascinating intersection between ancient wisdom and modern science. This intersection is where pharmacognosy meets drug patents, creating a unique landscape that shapes the future of medicine. What is a Drug Patent?
Introduction to Biomarkers in DrugDevelopment Biomarkers have become a cornerstone in the advancement of modern drugdevelopment and precision medicine. The use of biomarkers has transformed the pharmaceutical industry by allowing researchers to develop therapies that target specific pathways in diseases.
Non-human primates (NHPs), such as macaques and cynomolgus monkeys, have long served as a cornerstone in preclinical drugdevelopment due to their close genetic, anatomical and physiological resemblance to humans. Research using NHPs often requires detailed justification, approval by ethics committees and regular inspections.
Our annual look at the state of the drugdevelopment industry highlights a dual set of challenges complicating progress. Rising costs have become a persistent challenge for drugdevelopers, driven by a combination of internal and external pressures that have intensified in recent years.
Brain disorders are difficult to study and many drug candidates have failed in clinical trials, causing pharmaceutical companies to reduce their investments or even exit the field entirely. Why did you and your colleagues with the NASEM Forum decide to write this report? We all recognize the vast, unmet medical need.
As the clinical trial landscape evolves, drugdevelopers are faced with novel challenges and changes in study recruitment, trial size and structure, and more. The adoption of new innovations, strategies and technologies offers opportunities to address persistent challenges and develop suitable approaches for the future.
The pharmaceutical industry has faced significant challenges in recent years, including the loss of patents, increased regulatory scrutiny, and rising research and development costs.
The Future of Generic Drugs: How Technology is Revolutionizing the Industry As we continue to navigate the ever-changing landscape of healthcare, one thing is clear: technology is playing an increasingly important role in shaping the future of generic drugdevelopment. Will we see a surge in new treatments and medications?
Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drugdevelopment lifecycle. This was seen in the case of the BRAF V600E mutation test for melanoma patients receiving vemurafenib.
Exploring the transformative impact of large language models (LLMs) in molecular biology and drugdevelopment, discussing potential areas of applications and breakthroughs in personalized therapies. While enhancing molecular biology aspects, we also address ethical concerns ensuring responsible application of these models.
This dual role enables him to bridge research and clinical practice, ensuring scientific innovation is directly informed by patient care. “As At RadioMedix, he helps drive strategy, identifies promising candidates and isotopes, and oversees the development of both diagnostic and therapeutic agents – often in the form of theranostic pairs.
Clinical Research Organizations (CROs) are companies that provide support to the pharmaceutical and biotech industries by managing various aspects of the drugdevelopment process and conducting clinical trials. In this […] The post Clinical Research Organizations: Importance, Services, Selection Process and Future.
Drugdevelopment is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Highlighting data integration.
The Unseen Hurdles of Generic DrugDevelopment: Lessons Learned As the pharmaceutical industry continues to evolve, one thing remains constant: the pursuit of affordable, high-quality medications for patients worldwide. However, the journey to bringing a generic drug to market is often fraught with challenges.
AI in Pharma: Benefits, Risks and the Road Ahead AI is revolutionizing the drugdevelopment process, streamlining and accelerating every stage, from research to approval and marketing. This whitepaper explores the benefits and risks of AI in the pharmaceutical industry and examines its future.
Mitsubishi Research Institute and Astellas Forge Collaborative Initiative to Support Japanese Drug Discovery Startups and Boost Global Innovation Mitsubishi Research Institute, Inc. MRI) and Astellas Pharma Inc.
The role of academic research in generic drugdevelopment is multifaceted and crucial. Academic research plays a vital role in driving pharmaceutical innovation by fueling scientific discoveries…
Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value.
This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.
This dual-pronged approach allows Revolution Medicines to access capital tailored to its evolving needs without relinquishing equity or ceding commercial rights to a larger pharmaceutical partner. Source link
Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.
Artificial Intelligence (AI) is poised to transform the field of target discovery in drugdevelopment, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. With support from pharmaceutical companies, ultimately, the answer to this question should be yes.
On April 10, 2025, the US FDA announced that it has a long-term plan to eliminate conventional animal testing in drugdevelopment, starting with monoclonal antibodies (mAbs).[ 2] An overview of the 3Rs The FDA and other global regulatory health authorities have long embraced the 3Rs of animal research (replace, reduce, and refine).
The role of Real-World Evidence (RWE) in drugdevelopment helps in gaining a deep insight into how real-world data and experiences come together to shape impactful pharmaceutical solutions.
These core ADMET properties are fundamental to drugdevelopment across the industry, making them well-suited for pre-competitive collaboration. A fundamental shift in early-stage research With tightened funding and rising global competition, Haimson notes that demand for Inductive Bio’s platform is only growing.
Creating replicas of organs in vitro has been a goal of researchers for over a century. 1 This early work laid the foundation for a century of research on finding the optimal conditions for growing parts of organs in in vitro cultures, testing their functions and even mimicking many diseases.
The pharmaceutical industry is undergoing a major shift towards the development of breakthrough medicines and advanced therapies. This continued innovation highlights the complexity of the drugdevelopment process, particularly as the field is highly regulated by health authorities around the world.
— A new drugdeveloped by professors from the School of Pharmacy and Pharmaceutical Sciences at Binghamton University has received Food and Drug Administration (FDA) approval for the treatment of patients with Duchenne muscular dystrophy (DMD), a common genetic disease that mostly affects young boys.
Generic drugdevelopment is a complex process that requires a deep understanding of regulatory requirements and guidelines. Regulatory expertise plays a crucial role in ensuring that generic drugs meet the necessary standards for quality, safety, and efficacy. ” Scientific Research Publishing , 2024. ” U.S.
Dr Pooja Hingorani, Senior Medical Director of Oncology Early Development at AbbVie , shares her journey in STEM, from her early days in New Delhi to her impactful career in oncology research and drugdevelopment. Opportunities in clinical research and drugdevelopment were not always easy to come by.
Mass spectrometry imaging (MSI) enables the direct detection and quantitation of active pharmaceutical ingredients (APIs) and metabolites within tissue sections, making it widely regarded as a promising technique in the field of pharmacology and toxicology. References [1].
Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services pmjackson Wed, 11/13/2024 - 14:50 Greater Montréal, Québec, 11/13, 2024 — Altasciences , a trusted drugdevelopmentresearch partner for over 30 years, continues its commitment to providing world-class bioanalytical services.
The PPD clinical research business of Thermo Fisher Scientific has surveyed more than 150 drugdevelopers around the globe to gather annual data on trends in pharmaceuticalresearch and development. Applying artificial intelligence (AI) to drugdevelopment (e.g.,
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content